The invention provides: imidazole and imidazolium compounds of formulas (I) and (II): ##STR00001##
polymers containing a plurality of imidazolium-containing repeating units of formula (III′): ##STR00002##
and membranes and devices comprising the polymers. Also provided are methods of making the inventive compounds and polymers.

Methods for producing triflazoles or related derivatives thereof, and the resulting products are provided. For example, triflazoles can be prepared by reaction of trifluoromethanesulfonyl fluoride with an azole or azolate salt. Yields up to 78% are obtained. Triflazoles can be prepared by the reaction of a trifluoromethanesulfonyl fluoride with an N-silylazole in the presence of a basic catalyst. Yields up to 97% are obtained.

Methods for producing triflazoles or related derivatives thereof, and the resulting products are provided. For example, triflazoles can be prepared by reaction of trifluoromethanesulfonyl fluoride with an azole or azolate salt. Yields up to 78% are obtained. Triflazoles can be prepared by the reaction of a trifluoromethanesulfonyl fluoride with an N-silylazole in the presence of a basic catalyst. Yields up to 97% are obtained.

Provided herein are curcumin analogues that are able to interact with amyloid β (Aβ) and to attenuate the copper-induced crosslinking of Aβ. Also provided herein are methods of using the compounds in the treatment of Alzheimer's Disease or a related disorder.

Provided herein are curcumin analogues that are able to interact with amyloid β (Aβ) and to attenuate the copper-induced crosslinking of Aβ. Also provided herein are methods of using the compounds in the treatment of Alzheimer's Disease or a related disorder.

The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

##STR00001##

A non-aqueous electrolyte solution for a lithium secondary battery, and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, a non-aqueous solvent including a carbonate-based solvent and propyl propionate, and a compound represented by Formula 1. In some embodiments, the carbonate-based solvent is ethylene carbonate.

A non-aqueous electrolyte solution for a lithium secondary battery, and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, a non-aqueous solvent including a carbonate-based solvent and propyl propionate, and a compound represented by Formula 1. In some embodiments, the carbonate-based solvent is ethylene carbonate.

Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.11a, R.sup.11b, R.sup.11c, R.sup.11d, X, n.sup.1, n.sup.2, and n.sup.3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.11a, R.sup.11b, R.sup.11c, R.sup.11d, X, n.sup.1, n.sup.2, and n.sup.3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.